Jiménez, Isabel
Carabia, Júlia
Bobillo, Sabela
Palacio, Carles
Abrisqueta, Pau
Pagès, Carlota
Nieto, Juan C.
Castellví, Josep
Martínez-Ricarte, Francisco
Escoda, Lourdes
Perla, Cristóbal
Céspedes Torrez, Dennis H.
Boix, Joan
Purroy, Noelia
Puigdefàbregas, Lluís
Seoane, Joan
Bosch, Francesc
Crespo, Marta http://orcid.org/0000-0002-7732-7808
Funding for this research was provided by:
Instituto de Salud Carlos III (PI17/00950, PI17/00943, PI18/01392, PI16/01278)
Fundación Científica Asociación Española Contra el Cáncer (LABAECC, AECC_BCN)
Gilead Foundation (GLD16/00144, GLD18/00047)
Ministerio de Ciencia, Innovación y Universidades (RYC-2012-12018)
Fundación Alfonso Martín Escudero
Article History
Received: 20 March 2020
Accepted: 2 July 2020
First Online: 20 July 2020
Compliance with ethical standards
:
: M. C. has received research funding from Karyopharm, Pharmacyclics, Roche, Arqule and AstraZeneca. F.B. has received research funding and honoraria from Roche, Celgene, Takeda, AstraZeneca, Novartis, Abbie and Janssen. J.S. is a co-founder of Mosaic Biomedicals and Northern Biologics. J.S. received grant/research support from Mosaic Biomedicals, Northern Biologics and Roche/Glycart. PA has received honorarium for advisory and speaker faculty from Janssen, Roche, Celgene, and Abbvie. All remaining authors have declared no conflicts of interest.
: All animal experiments were approved by the local Ethical Committee for the Use of Experimental Animals. The use of primary cells from patients was approved by the local Clinical Research Ethics Committee according to the principles of the Declaration of Helsinki and after obtaining written informed consent from the patient.
: Not applicable.